William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating on September 17.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sami Corwin has given his Buy rating due to a combination of factors that highlight Cabaletta Bio’s potential for future growth. The company’s upcoming data release from the RESET-Myositis trial at the American College of Rheumatology conference is anticipated to provide significant insights. This data could reduce risks associated with the pivotal study by clarifying patient eligibility and demonstrating the durability of treatment benefits, which is crucial for the success of their registrational trial.
Additionally, Cabaletta Bio’s strategic approach to pricing and manufacturing efficiencies presents a promising financial outlook. The potential for premium pricing, comparable to high-cost biologics, combined with reduced manufacturing costs, suggests the possibility of achieving high profit margins. These factors, along with the company’s plans to submit a Biologics License Application by 2027, underpin Corwin’s positive outlook on the stock.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.